|
Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation |
Medicines for Europe |
05 Sep 2017 |
Health & Consumers |
|
Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health |
Medicines for Europe |
16 Jun 2017 |
Health & Consumers |
|
62% of Medicines Dispensed in Europe are Generic, according to IMS New Data |
Medicines for Europe |
15 Jun 2017 |
Health & Consumers |
|
EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access |
Medicines for Europe |
23 May 2017 |
Health & Consumers |
|
Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe |
Medicines for Europe |
09 May 2017 |
Health & Consumers |
|
Medicines for Europe can contribute much more to improve healthcare sustainability than described in the OECD “Health at a Glance 2016” report |
Medicines for Europe |
24 Nov 2016 |
Health & Consumers |
|
Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market |
Medicines for Europe |
19 Sep 2016 |
Health & Consumers |
